expand_moreexpand_less
Aeon
Al Jazeera
América Economía
Blitz
Buenos Aires Herald
Deutsche Welle
Dnevnik
E-International
Haaretz
Il Manifesto Global
Japan Today
Khaama PressMiddle East MonitorNikkei Asian ReviewOped Column
Pravda.sk
Project Syndicate
Psychology Today
RT.comSME.sk
South China Morning PostThe Asahi ShimbunThe DiplomatThe Japan NewsThe Japan Times
The Korea TimesThe Times of IsraelThe Times of Israel (Blogs)Večer
العين الإخبارية 
Toi StaffEmanuel FabianJacob MagidAgenciesReuters
Gideon LevyThe Japan News EditorialLuke TressLazar BermanGianluca PacchianiDavid Horovitz
Somdeep SenJeremy SharonSam Sokol
Belen FernandezCanaan Lidor
Andrew MitrovicaAmérica EconomíaThe Asahi ShimbunRon KampeasSue SurkesZvi Bar&x27ElAmy SpiroAmanda Borschel-DanCathryn J. PrinceRenee Ghert-ZandHanin MajadliYuli TamirNatan OdenheimerDavid RothkopfAndrew Lapin
Rami G KhouriCarolina LandsmannAmira HassEtan NechinEran Yashiv
Ali Fathollah-NejadJessica SteinbergGavriel FiskeCharlie SummersB. MichaelNoa LandauRachel MarsdenWilliam Noah GlucroftJames ShimanyulaMegan KangAhmad IbsaisMartina JaureguyAnshel PfefferAnonymous
|
|
Tom MurphySalon |
Eli Lilly expected a decision on donanemab in this year’s first quarter, which ends this month.
The 60-year-old Philadelphia company has posted annual losses for several years and sees a net loss of up to $680 million in the current fiscal year.
Many pharmacies, particularly the big chains, still don’t have enough workers behind the counter.
login
who are we?
contact us
qosheapp
